Carregant...
HCV Replicon Systems: Workhorses of Drug Discovery and Resistance
The development of direct-acting antivirals (DAAs) has revolutionized the state-of-the art treatment of HCV infections, with sustained virologic response rates above 90%. However, viral variants harboring substitutions referred to as resistance-associated substitutions (RASs) may be present in basel...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020-06-01
|
| Col·lecció: | Frontiers in Cellular and Infection Microbiology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/article/10.3389/fcimb.2020.00325/full |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|